Digitalis Ventures

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Elegen is a biotechnology company founded in 2017, focused on developing microfluidic technology to advance synthetic biology. Led by Dr. Matthew Hill, Elegen aims to revolutionize the field by engineering entire genomes and creating innovative DNA synthesizers. Their technology is designed to enhance the speed and efficiency of DNA sequence testing, thereby facilitating significant progress in biomedical research and healthcare applications. Through these efforts, Elegen seeks to contribute to the rapid development of solutions that address various challenges in the life sciences sector.

EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company focuses on developing gene therapies aimed at increasing the health and lifespan of domesticated animals, particularly dogs. Its innovative therapies utilize new DNA instructions to provide anti-aging treatments and address specific diseases in pets. The foundation of Rejuvenate Bio's research is rooted in work from the Wyss Institute at Harvard Medical School, and the company has established a gene therapy pipeline that targets chronic age-related diseases. By leveraging clinically validated gene targets and effective delivery methods, Rejuvenate Bio aims for long-lasting and well-tolerated gene expression, ultimately enhancing the quality of life for both animals and potentially humans facing chronic health challenges.

SeQure Dx specializes in providing safety data related to CRISPR gene editing therapies, focusing on both on-target and off-target effects. The company develops genomics diagnostic technologies that facilitate target profiling for gene editing, supporting the discovery, clinical development, and diagnostic processes. Its core technologies are designed to identify potential off-target sites prior to the initiation of therapy, ensuring comprehensive confirmation of actual genetic edits. This capability empowers gene editing therapeutics developers, physicians, and patients by enhancing the safety and efficacy of gene editing treatments.

Base5 Genomics, Inc. is a biotechnology firm focused on developing sequencing solutions for personalized healthcare. Founded in 2018 and based in Mountain View, California, the company aims to uncover the full genomic diversity in humans and other organisms. Its innovative solutions are designed to enhance the understanding of cancer biology, DNA damage and repair, genome organization, and gene regulation. By providing detailed genomic insights, Base5 Genomics enables the medical community to offer tailored treatments that cater to individual patient needs, thereby advancing the field of personalized medicine.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Good Therapeutics, Inc. is a biotechnology company based in Seattle, Washington, established in 2016. The company specializes in developing biotherapeutics and self-regulating drugs that provide therapeutic effects precisely when and where needed. Their innovative approach involves creating context-dependent protein drugs that can sense specific biomarkers and respond accordingly, thereby enhancing efficacy while minimizing systemic toxicity. Central to their technology is an algorithm designed to create allosterically-regulated proteins, which change shape upon binding to a biomarker, activating a therapeutic domain. Good Therapeutics is particularly focused on applications in immuno-oncology, aiming to leverage biological pathways to create therapies that maximize patient benefit without compromising safety.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. The company specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. Girihlet has developed patented technologies for profiling T cell receptors and sequencing mitochondrial DNA, utilizing novel, bias-free methods to analyze these genetic components. This approach aims to harness the potential of T cell receptors and mtDNA as biomarkers for diagnostics across various disorders, particularly those driven by T-cell-related autoimmune conditions. By employing deep sequencing and machine learning, Girihlet seeks to decode individual immune responses and guide effective therapeutic strategies, thereby contributing significantly to both clinical applications and advanced research in immunology.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company focuses on developing gene therapies aimed at increasing the health and lifespan of domesticated animals, particularly dogs. Its innovative therapies utilize new DNA instructions to provide anti-aging treatments and address specific diseases in pets. The foundation of Rejuvenate Bio's research is rooted in work from the Wyss Institute at Harvard Medical School, and the company has established a gene therapy pipeline that targets chronic age-related diseases. By leveraging clinically validated gene targets and effective delivery methods, Rejuvenate Bio aims for long-lasting and well-tolerated gene expression, ultimately enhancing the quality of life for both animals and potentially humans facing chronic health challenges.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.